Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy.

@article{Tan2009CombinationTW,
  title={Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy.},
  author={Xiaoyue Tan and Weichun He and Youhua Liu},
  journal={Kidney international},
  year={2009},
  volume={76 12},
  pages={
          1248-57
        }
}
Growing evidence suggests that active vitamin D slows the progression of chronic kidney diseases. Here we compared the individual renal protective efficacy of paricalcitol and trandolapril (an angiotensin-converting enzyme inhibitor) in obstructive nephropathy, and examined any potential additive effects of their combination on attenuating renal fibrosis and inflammation. Mice underwent unilateral ureteral obstruction and were treated individually with paricalcitol or trandolapril or their… Expand
Treatment combining aliskiren with paricalcitol is effective against progressive renal tubulointerstitial fibrosis via dual blockade of intrarenal renin
TLDR
A treatment combining aliskiren with paricalcitol better inhibits UUO-induced renal injury, and the mechanism of this synergy may involve more profound inhibition of the intrarenal renin-angiotensin system. Expand
Anti-inflammatory profile of paricalcitol in kidney transplant recipients.
TLDR
Paricalcitol administration to kidney transplant recipients has been found to have beneficial effects on inflammation, which may be associated with potential clinical benefits. Expand
Perfil antiinflamatorio del paricalcitol en el receptor de trasplante renal
TLDR
Paricalcitol administration to kidney transplant recipients has been found to have beneficial effects on inflammation, which may be associated with potential clinical benefits. Expand
Role of mitochondria in paricalcitol-mediated cytoprotection during obstructive nephropathy.
TLDR
The results suggest that paricalcitol confers a protective effect and reveal, as well, a possible AT(1) receptor-dependent protective effect that occurs at the mitochondrial level. Expand
Maxacalcitol ameliorates tubulointerstitial fibrosis in obstructed kidneys by recruiting PPM1A/VDR complex to pSmad3
TLDR
It is demonstrated that maxacalcitol (22-oxacalcitriol (OCT), an analog of active vitamin D, protects the kidney from TIF by suppressing the autoinduction of transforming growth factor-β1 (TGF- β1), and this findings provide a novel approach to inhibit the TGF-β pathway in fibrotic diseases. Expand
Early introduction of oral paricalcitol in renal transplant recipients. An open‐label randomized study
TLDR
In newly transplanted renal allograft recipients, paricalcitol reduced PTH and was well tolerated without negatively affecting kidney function, but did not significantly reduce/prevent albuminuria, improve parameters of vascular health, or influence allografted gene expression. Expand
The Role of Tubulointerstitial Inflammation in the Progression of Chronic Renal Failure
TLDR
The molecule 1,25-(OH)2D3 modulates PTC proliferation, suppresses fibroblast activation and matrix production, reduces epithelial mesenchymal transition and downregulates the genes of the renin-angiotensin system, which are critical steps in the development of a scarred kidney. Expand
New Insights on the Role of Vitamin D in the Progression of Renal Damage
TLDR
Human and sperimental models of CKD showed that vitamin D may interact with B and T lymphocytes and influence the phenotype and function of the antigen presenting cells and dendritic cells, promoting properties that favor the induction of tolerogenic T regulators rather than T effectory. Expand
Effect of paricalcitol and GcMAF on angiogenesis and human peripheral blood mononuclear cell proliferation and signaling.
TLDR
The results highlight the role of the vitamin D axis in chronic kidney disease, an axis which includes vitamin D, its receptor and vitamin D-binding protein-derived GcMAF. Expand
Anti‐Inflammatory Profile of Paricalcitol in Hemodialysis Patients: A Prospective, Open‐Label, Pilot Study
TLDR
Administration of paricalcitol administration to hemodialysis patients is associated with a beneficial effect on the inflammatory cytokine serum and gene expression profile of PBMC, which may contribute to the survival benefits of paricalscitol observed in clinical studies. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 52 REFERENCES
Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy.
TLDR
It is suggested that paricalcitol is able to ameliorate renal interstitial fibrosis in obstructive nephropathy, possibly by preserving tubular epithelial integrity through suppression of EMT. Expand
Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling.
TLDR
The results suggest that paricalcitol inhibits renal inflammatory infiltration and RANTES expression by promoting VDR-mediated sequestration of NF-kappaB signaling. Expand
Antiproteinuric effect of oral paricalcitol in chronic kidney disease.
TLDR
Reduction of proteinuria favored patients on paricalcitol, regardless of age, sex, race, diabetes mellitus, hypertension, or use of therapies to block the renin-angiotensin-aldosterone system (RAAS). Expand
Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol.
TLDR
Cardiac perivascular fibrosis and connective tissue growth factor were significantly increased in the remnant kidney groups, and further increased in paricalcitol-treated rats, regardless of the calcium, phosphate, or PTH levels. Expand
Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.
TLDR
Paricalcitol treatment reduced PTH concentrations more rapidly with fewer sustained episodes of hypercalcemia and increased Ca x P product than calcitriol therapy. Expand
Suppression of renin-angiotensin gene expression in the kidney by paricalcitol.
TLDR
These studies suggest that the beneficial effects of vitamin D receptor activators in experimental chronic renal failure are due, at least in part, to down-regulation of the renal renin-angiotensin system. Expand
Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats.
TLDR
19-nor can suppress the progression of renal insufficiency via mediation of the TGF-beta signaling pathway, and this effect is amplified when BP is controlled via renin-angiotensin system blockade. Expand
Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.
TLDR
Patients who receive paricalcitol while undergoing long-term hemodialysis appear to have a significant survival advantage over those who receive calcitriol. Expand
Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: Blockade of compensatory renin increase
TLDR
It is demonstrated that combination therapy with an AT1 receptor blocker and a vitamin D analog markedly ameliorated renal injury in the streptozotocin (STZ)-induced diabetes model due to the blockade of the compensatory renin rise by the Vitamin D analog, leading to more effective RAS inhibition. Expand
Differential effects of vitamin D receptor activators on vascular calcification in uremic rats.
TLDR
Different VDRAs have different effects on vascular calcification in uremic rats, independent of the serum calcium-phosphate product suggesting independent mechanisms. Expand
...
1
2
3
4
5
...